| From MAIA's closing valuation on Thursday, this $10.27 target suggests an upside potential of over 600%!
Critical Report Info:
Valuation: Recent clinical updates include THIO-101 Phase 2 data (180 mg dose cohort) showing median PFS of 5.6 months (>2x SOC) and median OS of 17.8 months, with two patients completing 33 cycles, as well as ESMOhighlighted 30-month survival in a refractory NSCLC patient completing two year therapy. With continued positive readouts, the ongoing THIO-104 Phase 3 study remains a key valuation catalyst, marking progression toward controlled clinical validation and potential registration. We maintain our valuation of $10.27 per share, contingent on successful execution by the company.
#2. Another Major Analyst Target Suggest Serious Upside Potential (Triple-Digit!).
Noble Capital Markets - $14.00 Target - (Potential upside of 850+% from Thursday's close.)
Key Report Details:
Conclusion. We believe the clinical progress from the Phase 2 trial have not been reflected in the st-ock price. Data from the Phase 2 THIO-101 Expansion/Registration patients could lead to an application for Early Approval, as well as confirm our high probability of Phase 3 success. We are reiterating our Outperform rating and $14 price target.
#3. MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opp. In $50Bn Immunotherapy Market.
MAIA Biotechnology’s 2026 momentum was recently highlighted in a shareholder letter.
Its lead drug, ateganosine, now in a Phase 3 trial for non-small cell lung cancer, shows strong potential for full FDA approval and broad clinical impact.
As the first direct telomere-targeting therapy, it addresses a $50Bn immunotherapy market with strong commercial potential.
With Fast Track status, impressive study results, and CEO Vlad Vitoc’s strategic vision, MAIA is poised for leadership and long-term growth in oncology innovation.
#4. A Potential Healthy Reversal Could Be Approaching For MAIA.
Technical analysis reveals MAIA has several oversold indicators, suggesting a possible reversal setup may be developing.
At close on Thursday, MAIA had a 9 and 14-Day Relative Strength Index both below 37% and a 9 and 14-Day Raw Stochastic below 17%.
These technical levels suggest a profile that may be currently undervalued.
#5. MAIA Biotechnology Strengthens Global Oncology Leadership With Ateganosine Advancements.
MAIA Biotechnology announced major progress in its ateganosine cancer therapy program, underscoring strong 2025 efficacy data and strategic growth milestones for 2026.
The FDA granted Fast Track status for ateganosine in NSCLC, enabling potential eligibility for Accelerated Approval and Priority Review.
With expanding FDA engagement and next-generation molecules entering trials, MAIA positions itself for sustained innovation and leadership in the $50+Bn immunotherapy market. -----
MAIA Biotechnology, Inc. (NYSE American: MAIA) is on our radar as coverage has been initiated.
Be on the lookout for updates heading your way shortly. Talk again soon.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 03/27/2026 and ending on 03/27/2026 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid eighty four thousand USD ("Funds"). These Funds were part of the one hundred ten thousand USD funds that TD Media LLC received from a third party named Sica Media LLC who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (MAIA:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/maia-4wvwp/#details | 
